Alphatec holdings, inc. (ATEC)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Net loss

-57,002

-28,975

-2,294

-29,925

-178,676

-12,882

-82,227

-15,459

-22,181

-14,355

-13,289

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

7,578

6,789

7,481

12,364

19,031

18,385

26,277

23,792

19,876

17,246

11,956

Goodwill and intangible assets impairment

-

-

-

2,189

165,171

0

-

-

-

-

-

Stock-based compensation

10,956

5,304

3,981

1,626

2,643

4,554

4,078

3,690

2,425

3,177

3,571

Amortization of debt discount and debt issuance costs

3,709

2,087

2,761

3,630

4,695

6,700

368

919

375

1,330

591

Amortization of right-of-use asset

930

-

-

-

-

-

-

-

-

-

-

Provision for doubtful accounts

242

164

-164

620

-

-

-

-

-

-

-

(Recovery) provision for excess and obsolete inventory

-

-

2,542

-

-

-

-

-

-

-

-

Impairment of goodwill and intangible assets

-

-

-

-

-

-

0

-

-

-

-

In-process research and development

-

-

-

-

98

102

0

341

0

1,000

-

Impairment of goodwill and intangible assets

-

-

-

2,189

-

-

-

-

-

-

-

In-process research and development paid in stock

-

-

-

-

-

-

-

-

-

-

3,011

Provision for doubtful accounts

-

-

-

-

584

522

404

859

1,094

945

5

Provision for excess and obsolete inventory

8,624

3,733

-

5,663

2,156

3,539

11,652

6,658

4,564

2,781

1,927

Deferred income tax benefit

-438

-1,405

-36

10

-333

251

816

-3,420

-4,345

-

-

Gain on settlement

-

6,168

-

-

-

-

-

-

-9,800

-

-

Beneficial conversion feature from convertible notes

242

-

-

-

-

-

-

-

-

-

-

Loss on sale of property and equipment, net

-

-

-

-

-

-

-

-

-

-

-53

Gain on sale of IMC Co. (discontinued operations)

-

-

-

-

-

-

-

-

-

-188

-

Litigation settlement

-

-

-

-

-

-

-

-

-

-

0

Deferred income tax expense

-

-

-

-

-

-

-

-

-

-1,945

141

Gain on sale of assets

-

-

856

-

-

-

-

-

-

-

-

Gain on sale of business

-

-

-

7,935

0

0

-

-

-

-

-

Loss on extinguishment of debt

-

-590

-

-3,863

0

0

-

-

-

-

-

Gain from change in estimated fair value of warrants

-

-

-12,044

687

-

-

-

-

-

-

-

Loss (Gain) on disposal of instruments

-127

-130

-281

-

-

-

-

-

-

-

-

Accretion to contingent consideration

289

846

-

-

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-590

-

-3,863

-

-

-

-

-

-

-

Other non-cash items

-

-

-

261

4,363

-1,913

-

-

-

-

-

Other non-cash items

-

-

-

-

-

-

1,464

2,158

0

-

-

Changes in operating assets and liabilities:
Restricted cash

-

-

-

-2,350

-4,400

6,750

0

0

-

-

-

Accounts receivable, net

1,298

396

-4,153

-8,000

-1,197

1,028

1,940

-382

5,004

-2,179

6,048

Inventories, net

14,712

5,014

-258

5,742

5,456

4,348

4,407

7,853

-1,084

-14,661

7,274

Prepaid expenses and other current assets

-186

268

-3,080

-1,074

-2,472

-4,863

-450

-1,681

-1,341

-2,130

-1,702

Other assets

-262

90

-348

-191

6

276

-64

-992

-1,216

679

-395

Other long-term assets

3,308

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other

6,647

1,677

-6,327

-3,498

-6,698

-34,774

55,171

-1,764

1,246

-2,591

-741

Accounts payable

6,003

16

-2,592

-4,865

3,209

-1,042

-3,853

-1,799

2,545

-5,203

-1,825

Deferred revenue

-

-261

223

-

-

-

-

-

-

-

-

Lease liability

2,239

-

-

-

-

-

-

-

-

-

-

Other long-term liabilities

-4,397

-4,367

-9,524

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-510

416

-628

1,261

277

Net cash used in operating activities

-33,121

-25,608

-8,729

-9,959

10,124

-20,271

7,807

11,593

13,408

-14,833

-5,548

Proceeds from sale of Noas Medical Company

-

-

-

-

-

-

-

-

-

-

383

Purchases of property and equipment

13,032

6,514

7,596

8,897

12,247

11,300

14,352

15,646

8,206

14,028

11,763

Cash paid for acquisition of intangible assets

-

400

-

250

0

0

750

1,750

690

2,300

1,353

Cash received from sale of equipment

-

-

1,101

28,046

5,000

30,350

28,000

0

10,000

-

0

Cash received from acquisition of Scient'x

-

-

-

-

-

-

-

-

-

1,589

-

Proceeds from sale of business, net

-

-

-

69,790

0

0

-

-

-

329

-

Cash received from sale of equipment

-

348

-

-

-

-

-

-

-

-

-

Cash received from sale of assets

-

-

-

1,316

0

300

0

0

-

-

-

Net cash used in investing activities

-13,032

-21,669

-6,495

61,959

-12,247

-11,000

-19,102

-19,396

-9,516

-14,410

-12,733

Financing activities:
Proceeds from public offering, net

53,848

-

-

-

-

-

-

-

-

-

-

Proceeds from sale of stock, net

-

-

24,386

114

-

-

-

-

-

-

-

Proceeds from sale of common stock, net

1,977

51,902

-

-

375

26

-

-

-

49,659

9,907

Exercise of stock options

-

-

-

-

-

-

8

76

104

213

38

Borrowings under lines of credit

114,710

90,459

96,244

118,482

141,583

163,067

154,622

121,232

2,350

20,174

5,768

Repayments under lines of credit

112,934

89,993

98,443

134,792

144,567

156,106

168,855

99,853

17,346

3,059

2,533

Principal payments on capital lease obligations

27

96

572

798

747

766

434

604

143

174

342

Cash paid for acquisition of SafeOp Surgical, Inc.

-

15,103

-

-

-

-

4,000

2,000

620

-

-

Proceeds from issuance of term debt, net

9,700

34,077

-

-

-

-

-

-

-

-

-

Principal payments on term loan and notes payable

-3,091

-32,464

-3,794

-54,444

-8,176

-5,837

-2,654

-12,375

-1,880

-23,268

-2,569

Purchase of noncontrolling interest

-

-

-

-

-

-

-

-

-

480

-

Net cash used in financing activities

64,183

53,885

17,821

-43,392

-6,532

30,734

10,687

8,476

-6,915

43,065

10,269

Effect of exchange rate changes on cash

29

-20

276

-85

149

-1,073

-288

902

521

-739

-218

Net decrease in cash

18,059

6,588

-

-

-

-

-

-

-

-

-

Supplemental disclosure of cash flow information:
Cash paid for interest

5,969

5,141

4,695

-

-

-

-

-

-

-

-

Cash paid for interest

-

-

-

7,368

7,627

5,885

3,973

2,592

2,322

4,245

2,245

Cash paid for income taxes

161

134

107

920

621

565

1,780

989

523

426

158

Net increase (decrease) in cash

-

-

2,873

8,523

-8,506

-1,610

-896

1,575

-2,502

13,083

-8,230

Supplemental disclosure of noncash investing and financing activities:
Common stock warrants issued with term loan draw

13,664

1,708

-

-

-

-

-

-

-

-

-

Common stock issued for achievement of SafeOp contingent consideration

-

-

-

-

-

-

250

1,000

8,000

2,500

-

Purchases of property and equipment in accounts payable

1,275

940

436

2,668

2,323

1,638

1,513

1,367

3,242

3,487

4,115

Cashless warrant conversion

-

-

-

1,074

0

0

-

-

-

-

-

Non-cash exercise of warrants

-

-

-

-

-

-

-

-

-

540

360

Reclassification of warrant liabilities to equity

-

-

14,355

-

-

-

-

-

-

-

-

Common stock issued for acquisition of intangible assets

-

-

473

-

-

-

-

-

-

-

-

Financing of insurance premiums by insurance provider

-

-

-

-

-

-

-

-

-

-

997

Issuance of common stock for litigation settlement

-

-

-

-

-

-

-

-

-

-

500

Capital lease additions included in property and equipment

-

-

156

-

243

1,212

0

2,225

0

-

96

Subscription receivable

-

-

300

-

-

-

-

-

-

-

-

Non-cash debt discount

-

-

-

-

0

650

0

-

-

-

-

Initial fair value of warrant liability

-

-

-

-

0

11,280

0

-

-

-

-

Issuance of common stock in connection with acquisitions

-

-

-

-

-

-

-

8,856

0

151,639

-

Initial fair value of warrant liability

-

-

-

-

-

-

0

-

-

-

-

Stock options issued in connection with Scient'x acquisition

-

-

-

-

-

-

-

-

-

1,040

-

SafeOp Surgical, Inc.
Accretion to contingent consideration

300

-

-

-

-

-

-

-

-

-

-

Common stock and warrants issued for the acquisition of SafeOp

-

12,529

-

-

-

-

-

-

-

-

-

Common stock issued for achievement of SafeOp contingent consideration

2,889

1,446

-

-

-

-

-

-

-

-

-